Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Goserelin (Zoladex) vs Nafarelin (Synarel)
An educational, source-based comparison of Goserelin (Zoladex) and Nafarelin (Synarel) — how each peptide works, what it's researched for, and what to know before going deeper.
Decapeptide GnRH agonist delivered via biodegradable subcutaneous implant. Suppresses gonadotropin and sex hormone production through pituitary desensitization.
- Prostate cancer
- Breast cancer (premenopausal)
- Endometriosis
- • FDA-approved.
- • Testosterone/estrogen flare; menopausal symptoms.
Intranasal GnRH agonist for endometriosis and central precocious puberty.
Decapeptide GnRH agonist administered intranasally; sustained receptor occupancy downregulates pituitary GnRH receptors, suppressing gonadotropin and sex steroid output.
- Endometriosis
- Central precocious puberty
- • FDA-approved.
- • Hypoestrogenic symptoms; limit treatment course for bone health.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Goserelin (Zoladex) | ZIPP trial | Lancet Oncology | 2005 | Adjuvant goserelin improved outcomes in premenopausal breast cancer. |
| Nafarelin (Synarel) | Nafarelin for endometriosis | Fertility & Sterility | 1990 | Comparable pain and lesion reduction to danazol with different side-effect profile. |
Side-effect & safety grid
- FDA-approved.
- Testosterone/estrogen flare; menopausal symptoms.
- FDA-approved.
- Hypoestrogenic symptoms; limit treatment course for bone health.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Goserelin (Zoladex) vs Nafarelin (Synarel) — Key differences
- Class: Goserelin (Zoladex) is classified as GnRH Agonist · Hormonal, while Nafarelin (Synarel) is GnRH Agonist · Endocrine.
- Primary research focus: Goserelin (Zoladex) — prostate cancer; Nafarelin (Synarel) — endometriosis.
- Tag: FDA-Approved · Oncology vs FDA-Approved · Endocrine.